Efruxifermin in Compensated Liver Cirrhosis Caused by MASH

肝硬化 内科学 胃肠病学 医学
作者
Mazen Noureddin,Mary Eugenia Rinella,Naga Chalasani,Guy W. Neff,K. Jean Lucas,Manuel E. Rodriguez,Madhavi Rudraraju,Rashmee Patil,Cynthia A. Behling,Mark Burch,Doreen C. Chan,Erik J. Tillman,Arian Zari,Brittany de Temple,Reshma Shringarpure,Meena Jain,Tim Rolph,Andrew Cheng,Kitty Yale
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:392 (24): 2413-2424 被引量:162
标识
DOI:10.1056/nejmoa2502242
摘要

BACKGROUND: In phase 2 trials involving patients with stage 2 or 3 fibrosis caused by metabolic dysfunction-associated steatohepatitis (MASH), efruxifermin, a bivalent fibroblast growth factor 21 (FGF21) analogue, reduced fibrosis and resolved MASH. Data are needed on the efficacy and safety of efruxifermin in patients with compensated cirrhosis (stage 4 fibrosis) caused by MASH. METHODS: In this phase 2b, randomized, placebo-controlled, double-blind trial, we assigned patients with MASH who had biopsy-confirmed compensated cirrhosis (stage 4 fibrosis) to receive subcutaneous efruxifermin (at a dose of 28 mg or 50 mg once weekly) or placebo. The primary outcome was a reduction of at least one stage of fibrosis without worsening of MASH at week 36. Secondary outcomes included the same criterion at week 96. RESULTS: A total of 181 patients underwent randomization and received at least one dose of efruxifermin or placebo. Of these patients, liver biopsy was performed in 154 patients at 36 weeks and in 134 patients at 96 weeks. At 36 weeks, a reduction in fibrosis without worsening of MASH occurred in 8 of 61 patients (13%) in the placebo group, in 10 of 57 patients (18%) in the 28-mg efruxifermin group (difference from placebo after adjustment for stratification factors, 3 percentage points; 95% confidence interval [CI], -11 to 17; P = 0.62), and in 12 of 63 patients (19%) in the 50-mg efruxifermin group (difference from placebo, 4 percentage points; 95% CI, -10 to 18; P = 0.52). At week 96, a reduction in fibrosis without worsening of MASH occurred in 7 of 61 patients (11%) in the placebo group, in 12 of 57 patients (21%) in the 28-mg efruxifermin group (difference from placebo, 10 percentage points; 95% CI, -4 to 24), and in 18 of 63 patients (29%) in the 50-mg efruxifermin group (difference from placebo, 16 percentage points; 95% CI, 2 to 30). Gastrointestinal adverse events were more common with efruxifermin; most events were mild or moderate. CONCLUSIONS: In patients with compensated cirrhosis caused by MASH, efruxifermin did not significantly reduce fibrosis at 36 weeks. (Funded by Akero Therapeutics; SYMMETRY ClinicalTrials.gov number, NCT05039450.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
wangjkone完成签到,获得积分10
刚刚
刚刚
水煮电吹风的应助被awake采纳,获得10
刚刚
小涵发布了新的文献求助10
2秒前
4秒前
Youdge的应助被hc采纳,获得10
4秒前
Lalala完成签到,获得积分10
5秒前
TSW发布了新的文献求助10
5秒前
爆米花的应助被脚踏实地i采纳,获得30
5秒前
rd发布了新的文献求助10
6秒前
霸气雯发布了新的文献求助20
7秒前
8秒前
星辰大海的应助被xx采纳,获得10
10秒前
郑睿涛发布了新的文献求助10
10秒前
12秒前
wei完成签到 ,获得积分10
12秒前
李明发布了新的文献求助10
14秒前
14秒前
lfz完成签到,获得积分10
15秒前
rd完成签到,获得积分10
16秒前
爆米花的应助被牧百川采纳,获得10
16秒前
楠猫要西柚完成签到,获得积分20
16秒前
官方电话完成签到 ,获得积分10
16秒前
明理的以亦完成签到,获得积分10
17秒前
wanci的应助被renn采纳,获得20
18秒前
飞飞鱼完成签到,获得积分10
18秒前
学术新星发布了新的文献求助10
18秒前
19秒前
Ren发布了新的文献求助10
19秒前
19秒前
传奇3的应助被和蔼的茅草根采纳,获得10
20秒前
风里等你完成签到,获得积分10
21秒前
22秒前
zhu完成签到,获得积分10
22秒前
22秒前
serena完成签到,获得积分10
24秒前
25秒前
FashionBoy的应助被ZZSY采纳,获得10
26秒前
科研通AI6.4的应助被TSW采纳,获得20
26秒前
27秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183449
求助须知:如何正确求助?哪些是违规求助? 9572834
关于积分的说明 21827509
捐赠科研通 7780646
什么是DOI,文献DOI怎么找? 3434016
关于科研通互助平台的介绍 2558189
邀请新用户注册赠送积分活动 2480371